Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C

References

• Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 264–70
   PubMed Web of Science ®Google Scholar
• Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209–12
   PubMed Web of Science ®Google Scholar
• Dalgard O, Egeland A, Skaug K, Vilimas K, Steen T. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 2004; 39: 74–80
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Ware JE, Jr, Bayliss MS, Pianko S, Albrecht JK, Cort S, et al. The effects of interferon alpha-2b in combination with ribavirin on health-related quality of life and work productivity. J Hepatol 2001; 34: 140–7
   PubMed Web of Science ®Google Scholar
• Ware JE, Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30: 550–5
   PubMed Web of Science ®Google Scholar
• Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704–8
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485–92
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426–32
   PubMed Web of Science ®Google Scholar
• Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 83–7
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–55
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65
   PubMed Web of Science ®Google Scholar
• EASL International Consensus Conference on Hepatitis C. Paris, 26–28, February, 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999;30:956–61.
   Google Scholar
• National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002. June 10–12, 2002. Hepatology 2002;36 Suppl 1:S3–20.
   Google Scholar
• Wejstal R, Alaeus A, Fischler B, Reichard O, Uhnoo I, Weiland O. Chronic hepatitis C: updated Swedish consensus. Scand J Infect Dis 2003; 35: 445–51
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 1302–11
   PubMed Web of Science ®Google Scholar
• Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30: 1299–301
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32: 654–9
   PubMed Web of Science ®Google Scholar
• Doglio A, Laffont C, Caroli-Bosc FX, Rochet P, Lefebvre J. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 1999; 37: 1567–9
   PubMed Web of Science ®Google Scholar
• Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34: 2259–66
   PubMed Web of Science ®Google Scholar
• Yun Z, Lara C, Johansson B, Lorenzana de Rivera I, Sonnerborg A. Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol 1996; 49: 155–60
   PubMed Web of Science ®Google Scholar
• Sullivan M, Ware JE, Karlsson J, Sahlgrenska sjukhuset. Sektionen för vårdsforskning. SF-36 hälsoenkät: svensk manual och tolkningsguide (Swedish manual and interpretation guide). Göteborg: Sahlgrenska sjukhuset Sektionen för vårdforskning; 1994.
   Google Scholar
• Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–83
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ware JE, Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40–66
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ware JE, Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247–63
   PubMed Web of Science ®Google Scholar
• Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999; 15: 141–55
   PubMed Web of Science ®Google Scholar
• Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409–17
   PubMed Web of Science ®Google Scholar
• Schvarcz R, Glaumann H, Reichard O, Weiland O. Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C. J Viral Hepat 1999; 6: 237–42
   PubMed Web of Science ®Google Scholar
• Hollander A, Glaumann H, Weiland O. Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre. Scand J Gastroenterol 2004; 39: 164–7
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061–9
   PubMed Web of Science ®Google Scholar
• Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645–52
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Morgan TR, Ghany MG, Wright EC, Group atH-CT. The impact of peginterferon (pegifn) and ribavirin dosing on sustained virologic response in patients with chronic hepatitis C virus undergoing retreatment in the halt-C trial. Hepatology 2004;40 Suppl 1:314A.
   PubMed Web of Science ®Google Scholar